J&J: Inflationary Pressures ‘Here To Stay’ With Impact Likely Into 2023

 
• By Jessica Merrill

Johnson & Johnson reported 3% sales growth in the second quarter, led by pharmaceuticals, which were positive financial results given persistent macroeconomic challenges and a currency headwind.

J&J logo
J&J reported Q3 sales growth • Source: Shutterstock

More from Earnings

More from Business